Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 15,243,078 shares of a nominal value of DKK 30,486,156, equivalent to 4.92% of Novozymes A/S’ share capital and 1.92% of the voting rights.
Major shareholder announcement
In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds 4.92% of the B shares in Novozymes, previously reported at 5.10% in company announcement no. 51, October 2016.
| Source: Novonesis (Novozymes A/S)
Recommended Reading
-
Please read the full announcement in PDF. Attachments 2025_36_Major_Shareholders_Announcement Novozymes B 16 July 2025_Final ...
Read More -
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains...
Read More